Is epoetin alfa a treatment option for chemotherapy-related anemia in children?

Medical and Pediatric Oncology

Volumn 39, Issue 4, 2002, Pages 455-458

  Büyükpamukçu, Münevver ^a   Varan, Ali ^a   Kutluk, Tezer ^a   Akyudie, Canan ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Anemia; Chemotherapy complications; Childhood cancer; Epoetin alfa

Indexed keywords

RECOMBINANT ERYTHROPOIETIN;

ADOLESCENT; ANEMIA; ANTINEOPLASTIC ACTIVITY; BLOOD TRANSFUSION; CANCER CHEMOTHERAPY; CANCER PATIENT; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; CONFERENCE PAPER; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; TREATMENT INDICATION; TREATMENT OUTCOME;

ADOLESCENT; ANEMIA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOOD TRANSFUSION; CHILD; CHILD, PRESCHOOL; EPOETIN ALFA; FEMALE; HEMOGLOBINS; HUMANS; INFANT; INJECTIONS, SUBCUTANEOUS; MALE; NEOPLASMS; TREATMENT OUTCOME;

EID: 0036782273     PISSN: 00981532     EISSN: None     Source Type: Journal    
DOI: 10.1002/mpo.10185     Document Type: Conference Paper

References (12)

1. Erythropoietin for anemia in cancer patients
2. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: Results of a randomized, double-blind, placebo-controlled trial
3. Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice
4. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: Results from a prospective community oncology study
5. Once-weekly dosing of epoetin alfa is similar to three-times-weekly dosing in increasing hemoglobin and quality of life
6. Recombinant erythropoietin in acute chemotherapy-induced anemia of children with cancer
7. Erythropoietin reduces volume of red cell transfusions required in some subsets of children with acute lymphocytic leukemia
8. Prevention of anemia with r-HuEPO in children with Ewing's or osteogenic sarcoma
9. Recombinant human erythropoietin reduces the need for erythrocyte and platelet transfusion in pediatric patients with sarcoma: A randomized, double-blind, placebo-controlled trial
10. Treatment with recombinant human erythropoietin in children with malignancies
11. Reduction in transfusion requirements with early epoetin alfa treatment in pediatric patients with solid tumors: A case-control study
12. Recombinant human erythropoietin treatment for chemotherapy-related anemia in children